InsidersTradesSigma
Track the HLB제약 share price and the full management transaction log of the company, a listed equity based in South Korea. Shares trade on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, HLB제약 has recorded 58 public disclosures. Market capitalisation: €272.9bn. The latest transaction was reported on 4 June 2026 (Other). Among the most active insiders: HLB생명과학. The full history is free.
58
Insider Decl.
n/a
Thresholds
n/a
11 ops.
Buy Volume
n/a
1 ops.
Sell Volume
5Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,646 of 29,024 companies
34.9
score / 100
Value29
Quality41
FCF yld-2.6%
Earn yld1.8%
EV/EBITDA28.3x
ROE-40%
Gross mgn52%
Net mgn2.2%
Debt/EBITDA2.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 June 2026
Declarations58 total
25 of 58 declarations
About HLB제약
HLB제약 is a company in the health and pharmaceutical sector, listed on the XKRX market. It specializes in the development and commercialization of pharmaceutical products.